Avastin Treatment Reduces Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity

REFERENCES

• Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283–290.
   PubMed Web of Science ®Google Scholar
• Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5½ years after randomization. Arch Ophthalmol. 1996;114:417–424.
   Google Scholar
• Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Ophthalmologic outcomes at 10 years. Arch Ophthalmol. 2001;119:1110–1118.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129–134.
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035–1047.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina (Philadelphia, Pa) 2006;26:383–390.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372.e5.
   PubMed Web of Science ®Google Scholar
• Emerson MV, Lauer AK, Flaxel CJ et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 2007;27:439–444.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1–1695.15.
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Oshima Y, Sakaguchi H et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571–1580, 1580.e1.
   Web of Science ®Google Scholar
• Hsu J, Kaiser RS, Sivalingam A et al. Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina (Philadelphia, Pa) 2007;27:1013–1019.
   PubMed Web of Science ®Google Scholar
• Spierer A, Rabinowitz R, Pri-Chen S, Rosner M. An increase in superoxide dismutase ameliorates oxygen-induced retinopathy in transgenic mice. Eye (Lond) 2005;19:86–91.
   Google Scholar
• Rabinowitz R, Katz G, Rosner M, Pri-Chen S, Spierer A. The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:843–848.
   PubMed Web of Science ®Google Scholar
• Smith LE, Wesolowski E, McLellan A et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101–111.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999;27:14–21.
   PubMed Web of Science ®Google Scholar
• D’Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res 1993;46:135–142.
   PubMed Web of Science ®Google Scholar
• Higgins RD, Yu K, Sanders RJ, Nandgaonkar BN, Rotschild T, Rifkin DB. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Curr Eye Res 1999;18:20–27.
   PubMed Web of Science ®Google Scholar
• Margo CE, Lee A. Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefes Arch Clin Exp Ophthalmol 1995;233:366–370.
   PubMed Web of Science ®Google Scholar
• Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905–909.
   PubMed Web of Science ®Google Scholar
• Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219–1228.
   PubMedGoogle Scholar
• Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133–140.
   PubMedGoogle Scholar
• Brady-McCreey KM, McCreey CJ, Sriram Vet al. Serum vascular endothelial growth factor and threshold of retinopathy of prematurity (abstract). In: Annual Meeting of the American Academy of Ophthalmology; 4th-8th November 2001; New Orleans. San Francisco: American Academy of Ophthalmology; 2001. Abstract 113.3.
   Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336–339.
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233–237.
   PubMedGoogle Scholar
• Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727–1730.
   PubMed Web of Science ®Google Scholar
• Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450–1455.
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Berrocal AM, Murray TG et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina (Philadelphia, Pa) 2008;28:S13–S18.
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina (Philadelphia, Pa) 2008;28:S19–S25.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina (Philadelphia, Pa) 2008;28:831–838.
   PubMed Web of Science ®Google Scholar
• Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061–1063.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang J, Guan Y et al. Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:919–927.
   Google Scholar
• Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina (Philadelphia, Pa) 2006;26:262–269.
   PubMed Web of Science ®Google Scholar
• Luthra S, Narayanan R, Marques LE et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (Philadelphia, Pa) 2006;26:512–518.
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S et al. Tübingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995–1002.
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792–799.
   PubMed Web of Science ®Google Scholar
• Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27:622–647.
   PubMed Web of Science ®Google Scholar
• Chan-Ling T, Tout S, Holländer H, Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1992;33:2128–2147.
   PubMed Web of Science ®Google Scholar
• Wong HK, Lahdenranta J, Kamoun WS et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 2010;70:3483–3493.
   PubMed Web of Science ®Google Scholar
• Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, Goldenberg-Cohen N. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis 2009;15:2326–2338.
   PubMed Web of Science ®Google Scholar
• Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 2010;88:862–867.
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545–2552.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 2010;17:1042–1051.
   PubMed Web of Science ®Google Scholar